OTC Medicines

(WASHINGTON, D.C.) — Consumer Healthcare Products Association (CHPA) President & CEO Scott Melville today released the following statement in response to the White House’s executive order, “Lowering Drug Prices by Once Again Putting Americans First,” issued this week.

(WASHINGTON, D.C.) — The Consumer Healthcare Products Association (CHPA) today responded to an announcement from the Department of Commerce this week regarding the initiation of a Section 232 investigation into the national security implications of pharmaceutical imports, including finished drug products, active pharmaceutical ingredients (APIs), and other critical materials:

(WASHINGTON, D.C.) — The Consumer Healthcare Products Association (CHPA) today released the following statement echoing concerns U.S. Reps. Bob Latta (OH-05), Dan Crenshaw (TX-02), and Mariannette Miller-Meeks (IA-01) raised to the U.S. Food and Drug Administration (FDA), urging the Agency to strike the simultaneous marketing portion of the preamble that is tied to the final rule for Nonprescription Drug Product With an Additional Condition for Nonprescription Use (ACNU):

(Washington, D.C.) – The Consumer Healthcare Products Association (CHPA) released the below statement today following a House Energy and Commerce Subcommittee on Health hearing featuring testimony from Kevin Menzel, President of Focus Consumer Healthcare, a CHPA member company, and other industry experts, to discuss the importance of reauthorizing the OTC Monograph Drug User Fee Program (OMUFA).

CHPA President and CEO Scott Melville released a statement today following the U.S. Senate confirming the nomination of Dr. Martin Makary to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA) by a recorded vote of 56-44.

(JACKSON, Miss) – The Consumer Healthcare Products Association (CHPA) applauds Mississippi Representative Stacey Wilkes, Senator Hob Bryan, and Governor Tate Reeves for passing and signing legislation into law requiring all manufacturers of over-the-counter (OTC) medicines containing pseudoephedrine (PSE) to participate in supporting the costs and administration of the National Precursor Log Exchange (NPLEx) system – a real-time stop-sale technology that allows retailers to enforce PSE sales limits and assist law enforcement in preventing illegal PSE sales. This important step not only strengthens the NPLEx system overall, but it enhances its long-term viability in preventing illegal sales of medicines containing PSE in Mississippi.

“CHPA and its member companies look forward to working with Secretary Kennedy to advance policies that will enhance American consumers’ access to safe, effective, and affordable self-care options. With a growing demand for OTC medicines, dietary supplements, and OTC medical devices, it is imperative that our nation’s healthcare leaders expand access, streamline regulatory pathways, and reinforce public confidence through transparent, data-driven decisions. This can be achieved through the reauthorization of the Over-the-Counter Monograph Drug User Fee Program (OMUFA), Rx-to-OTC switch improvements, and the modernization of the more than 30-year-old Dietary Supplement Health and Education Act (DSHEA).

(WASHINGTON, D.C.) – Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville released the below statement following President Trump imposing a 25% tariff on imports from Mexico and Canada, which were originally set to take effect Tuesday, Feb. 4 at 12:01 a.m. EST. As of this morning, the Trump Administration has agreed to pause sweeping tariffs on Mexico for one month while the two sides work on an agreement.